Biopolym. Cell. 2016; 32(6):450-460.
http://dx.doi.org/10.7124/bc.00093C
Molecular Biomedicine
Identification and characterization of six new mutations in GLB1 gene in Ukrainian patients with GM1 gangliosidosis and Morquio B disease
1, 2Mytsyk N. Y., 2Gorovenko N. G.
  1. National Children's Specialized Hospital Okhmatdyt, Ministry of Health of Ukraine
    28/1, Chornovola Str., Kyiv, Ukraine, 01135
  2. State Institute of Genetic and Regenerative Medicine, NAMS of Ukraine
    67, Vyshhorodska Str., Kyiv, Ukraine, 04114

Abstract

GM1-gangliosidosis (MIM# 230500) and mucopolysaccharidosis IV (Morquio B, MIM# 230500) are autosomal-recessive diseases, which belong to the group of lysosomal storage disorders and are caused by changes in the structure of the same gene, GLB1. The mutations in GLB1 lead to deficiency in acid β-galactosidase, and, as a result, the accumulation of GM1-gangliosidosis and keratan sulphate in the patients’ lysosomes. Aim. To analyze the spectrum of mutations in GLB1 in Ukrainian patients with GM1 gangliosidosis and Morquio B disease. Results. We analyzed GLB1 in 25 Ukrainian patients with the diagnosis of GM1-gangliosidosis and one patient with Morquio B disease; 52 alleles were analyzed. Seventeen types of pathogenic mutations were identified, including 11 missense replacements, three deletions, one insertion and two mutations in the splicing site. The missense mutation p.His281Tyr (c.841C>T) in exon 8 was found to be the most common, as it was found in 19 out of 52 mutant alleles (36.5 %) of all the examined patients. The study allowed to identify six new mutations, which had not been found in any databases or previously described in scientific literature, including three deletions (c.699delG, c.833delG, c.1203_1205delTTA), two missense replacements (p.Gly243Arg, p.Gly262Ala) and one mutation in the splicing site (IVS12+8T>C). Conclusions. Our results can be used for a precise molecular diagnostics of patients with GM1-gangliosidosis and Morquio B disease and prenatal diagnostics in the high risk families.
Keywords: GM1-gangliosidosis, Morquio B disease, gene GLB1
Full text: (PDF, in English)

References

[1] Johnson WG. Chapter 34 – β-Galactosidase deficiency: GM1 gangliosidosis, Morquio B disease, and galactosialidosis. In: Rosenberg’s molecular and genetic basis of neurological and psychiatric disease (Fifth Edition). Academic Press. 2015; 385–94.
[2] Ohto U, Usui K, Ochi T, Yuki K, Satow Y, Shimizu T. Crystal structure of human β-galactosidase: structural basis of Gm1 gangliosidosis and morquio B diseases. J Biol Chem. 2012;287(3):1801-12.
[3] Caciotti A, Garman SC, Rivera-Colón Y, Procopio E, Ca-tarzi S, Ferri L, Guido C, Martelli P, Parini R, Antuzzi D, Battini R, Sibilio M, Simonati A, Fontana E, Salviati A, Akinci G, Cereda C, Dionisi-Vici C, Deodato F, d’Amico A, d’Azzo A, Bertini E, Filocamo M, Scarpa M, di Rocco M, Tifft CJ, Ciani F, Gasperini S, Pasquini E, Guerrini R, Donati MA, Morrone A. GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings. Biochim Biophys Acta. 2011;1812(7):782–90.
[4] Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet. 1997;101(3):355-8.
[5] Nelson J, Crowhurst J, Carey B, Greed L. Incidence of the mucopolysaccharidoses in Western Australia. Am J Med Genet A. 2003;123A(3):310-3.
[6] Bidchol AM, Dalal A, Trivedi R, Shukla A, Nampoothiri S, Sankar VH, Danda S, Gupta N, Kabra M, Hebbar SA, Bhat RY, Matta D, Ekbote AV, Puri RD, Phadke SR, Gowrishankar K, Aggarwal S, Ranganath P, Sharda S, Kamate M, Datar CA, Bhat K, Kamath N, Shah H, Krishna S, Gopinath PM, Verma IC, Nagarajaram HA, Satyamoorthy K, Girisha KM. Recurrent and novel GLB1 mutations in India. Gene. 2015;567(2):173-81.
[7] Mytsyk NY, Olkhovych NV, Gorovenko NG. Selective biochemical screening lysosomal storage diseases by TLC of oligo-saccharides. Visnyk problem biologii i mediciny. 2016; 1(126):222–7.
[8] Trofimova NS, Olkhovych NV, Gorovenko NG. Application of biochemical screening studies in early diagnostics of muco-polysaccharidosis. Visnyk problem biologii i mediciny. 2015; 2(123):245–50.
[9] Silva CM, Severini MH, Sopelsa A, Coelho JC, Zaha A, d'Azzo A, Giugliani R. Six novel beta-galactosidase gene mutations in Brazilian patients with GM1-gangliosidosis. Hum Mutat. 1999;13(5):401-9.
[10] Oshima A, Yoshida K, Shimmoto M, Fukuhara Y, Sakuraba H, Suzuki Y. Human beta-galactosidase gene mutations in morquio B disease. Am J Hum Genet. 1991;49(5):1091-3.
[11] Iwasaki H, Watanabe H, Iida M, Ogawa S, Tabe M, Higaki K, Nanba E, Suzuki Y. Fibroblast screening for chaperone therapy in beta-galactosidosis. Brain Dev. 2006;28(8):482-6.
[12] Paschke E, Milos I, Kreimer-Erlacher H, Hoefler G, Beck M, Hoeltzenbein M, Kleijer W, Levade T, Michelakakis H, Radeva B. Mutation analyses in 17 patients with deficiency in acid beta-galactosidase: three novel point mutations and high correlation of mutation W273L with Morquio disease type B. Hum Genet. 2001;109(2):159-66.
[13] Hofer D, Paul K, Fantur K, Beck M, Bürger F, Caillaud C, Fumic K, Ledvinova J, Lugowska A, Michelakakis H, Radeva B, Ramaswami U, Plecko B, Paschke E. GM1 gangliosidosis and Morquio B disease: expression analysis of missense mutations affecting the catalytic site of acid beta-galactosidase. Hum Mutat. 2009;30(8):1214-21.
[14] Boustany RM, Qian WH, Suzuki K. Mutations in acid beta-galactosidase cause GM1-gangliosidosis in American patients. Am J Hum Genet. 1993;53(4):881-8.
[15] Santamaria R, Blanco M, Chabás A, Grinberg D, Vilageliu L. Identification of 14 novel GLB1 mutations, including five deletions, in 19 patients with GM1 gangliosidosis from South America. Clin Genet. 2007;71(3):273-9.
[16] Sperb F, Vairo F, Burin M, Mayer FQ, Matte U, Giugliani R. Genotypic and phenotypic characterization of Brazilian patients with GM1 gangliosidosis. Gene. 2013;512(1):113-6.
[17] Coutinho MF, Lacerda L, Macedo-Ribeiro S, Baptista E, Ribeiro H, Prata MJ, Alves S. Lysosomal multienzymatic complex-related diseases: a genetic study among Portuguese patients. Clin Genet. 2012;81(4):379-93.
[18] Hofer D, Paul K, Fantur K, Beck M, Roubergue A, Vellodi A, Poorthuis BJ, Michelakakis H, Plecko B, Paschke E. Phenotype determining alleles in GM1 gangliosidosis patients bearing novel GLB1 mutations. Clin Genet. 2010;78(3):236-46.
[19] Santamaria R, Chabás A, Callahan JW, Grinberg D, Vilageliu L. Expression and characterization of 14 GLB1 mutant alleles found in GM1-gangliosidosis and Morquio B patients. J Lipid Res. 2007;48(10):2275-82.
[20] Al-Jasmi FA, Tawfig N, Berniah A, Ali BR, Taleb M, Hertecant JL, Bastaki F, Souid AK. Prevalence and Novel Mutations of Lysosomal Storage Disorders in United Arab Emirates : LSD in UAE. JIMD Rep. 2013;10:1-9.
[21] Celtikçi B, Aydın Hİ, Sivri S, Sönmez M, Topçu M, Ozkara HA. Four novel mutations in the β-galactosidase gene identified in infantile type of GM1 gangliosidosis. Clin Biochem. 2012;45(7-8):571-4.
[22] Yang CF, Wu JY, Tsai FJ. Three novel beta-galactosidase gene mutations in Han Chinese patients with GM1 gangliosidosis are correlated with disease severity. J Biomed Sci. 2010;17:79.
[23] Lei HL, Ye J, Qiu WJ, Zhang HW, Han LS, Wang Y, Gu XF. Beta-galactosidase deficiencies and novel GLB1 mutations in three Chinese patients with Morquio B disease or GM1 gangliosidosis. World J Pediatr. 2012;8(4):359-62.